Spyre Therapeutics (SYRE) Payables (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Payables came in at $56.0 million in Q1 2026, up 20.33% YoY from $46.5 million in Q1 2025, and up 76.37% on a QoQ basis from $31.7 million in Q4 2025.
Spyre Therapeutics (SYRE) Payables (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Payables data on file, last reported at $56.0 million in Q1 2026.
- Quarterly Payables rose 20.33% year-over-year to $56.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.0 million (up 20.33% YoY) and the FY2025 annual result came in at $31.7 million, up 23.22% from the prior year.
- Payables advanced to $56.0 million in Q1 2026, from $31.7 million in the prior quarter.
- In the past five years, Payables ranged from a high of $63.6 million in Q2 2025 to a low of $2.0 million in Q2 2022.
- A 5-year average of $20.6 million and a median of $13.8 million in 2023 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables jumped 1108.58% — and 2024, when it plunged 75.19%.
- Tracing SYRE's Payables over 5 years: stood at $4.2 million in 2022, then slumped by 45.28% to $2.3 million in 2023, then surged by 1026.25% to $25.7 million in 2024, then gained by 23.22% to $31.7 million in 2025, then surged by 76.37% to $56.0 million in 2026.
- The last three Payables figures came in at $56.0 million (Q1 2026), $31.7 million (Q4 2025), and $18.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | 37.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.07 Mn |
| Mar 31, 2026 | 55.95 Mn |
| Dec 31, 2025 | 31.72 Mn |
| Sep 30, 2025 | 18.48 Mn |
| Jun 30, 2025 | 63.61 Mn |
| Mar 31, 2025 | 46.50 Mn |
| Dec 31, 2024 | 25.75 Mn |
| Sep 30, 2024 | 29.91 Mn |
| Jun 30, 2024 | 5.87 Mn |
| Mar 31, 2024 | 5.70 Mn |
| Dec 31, 2023 | 2.29 Mn |
| Sep 30, 2023 | 9.19 Mn |
| Jun 30, 2023 | 23.66 Mn |
| Mar 31, 2023 | 2.06 Mn |
| Sep 30, 2022 | 4.18 Mn |
| Jun 30, 2022 | 1.96 Mn |
| Mar 31, 2022 | 2.98 Mn |
| Dec 31, 2021 | 3.32 Mn |
| Sep 30, 2021 | 1.86 Mn |
| Jun 30, 2021 | 2.22 Mn |